How has been the historical performance of Titan Biotech?

Answer:The historical performance of Titan Biotech shows a fluctuating trend in key financial metrics over the years.

Breakdown:
Titan Biotech's net sales peaked at 164.07 Cr in Mar'24 but decreased to 156.45 Cr in Mar'25, following a gradual rise from 144.00 Cr in Mar'23. The total operating income mirrored this trend, with a high of 164.07 Cr in Mar'24 and a drop to 156.45 Cr in Mar'25. Raw material costs decreased from 80.89 Cr in Mar'24 to 75.48 Cr in Mar'25, while employee costs increased from 23.71 Cr to 26.38 Cr during the same period. Consequently, the operating profit (PBDIT) fell from 36.03 Cr in Mar'24 to 29.34 Cr in Mar'25, reflecting a decline in operating profit margin from 20.89% to 16.25%. Profit before tax also decreased from 31.53 Cr to 24.37 Cr, leading to a profit after tax of 18.27 Cr in Mar'25, down from 23.66 Cr in Mar'24. The consolidated net profit showed a similar decline, dropping to 21.53 Cr in Mar'25 from 24.85 Cr in Mar'24. On the balance sheet, total assets increased from 157.03 Cr in Mar'24 to 174.71 Cr in Mar'25, while total liabilities rose from 134.52 Cr to 174.71 Cr. Cash flow from operating activities remained relatively stable, with a slight decrease from 21.00 Cr in Mar'24 to 20.00 Cr in Mar'25, and the closing cash and cash equivalents increased to 5.00 Cr in Mar'25 from 2.00 Cr in Mar'24. Overall, Titan Biotech's financial performance indicates challenges in profitability despite growth in total assets.